Pre-Implantation Genetic Diagnosis (PGD) is advanced testing of embryos for genetic abnormalities including:
Performing genetic testing prior to an embryo transfer increases the probability of transferring unaffected embryos and decreases the chances of genetically-affected offspring.
EmbryoSelect™ Aneuploidy Screening
Aneuploidy, or the presence of too few or too many chromosomes, is a genetic abnormality that is a major contributor to the failure of IVF cycles and is the most common cause of miscarriage.
Historically, the quality of an embryo (its development and appearance) has been used to determine which embryos to transfer to the uterus in IVF treatment.
EmbryoSelect Aneuploidy Screening improves the embryo selection process by more accurately identifying embryos that have the greatest potential to result in a healthy pregnancy. EmbryoSelect Aneuploidy Screening involves the biopsy of a small number of cells from early embryos before transfer to the uterus. The cells are then analyzed to distinguish embryos that have a normal chromosome number or are “euploid” from those that have an abnormal chromosome number or “aneuploid”.
By only transferring those embryos determined to be euploid, patients can improve their chances of success with IVF by excluding the abnormal embryos that lead to miscarriage or birth defects.
EmbryoSelect gives patients the benefit of and confidence in electing single embryo transfer for IVF.